Obesity, inflammation, and lung injury (OILI): The good

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Wang, Cheryl ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLYCOPROTEIN; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; OMENTIN; PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 5; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN; ZINC ALPHA2 GLYCOPROTEIN; CYTOKINE; EYE PROTEIN; GDF15 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IL6 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; ITLN1 PROTEIN, HUMAN; LECTIN; MEMBRANE PROTEIN; SEMINAL PLASMA PROTEIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; SFRP5 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; ZN-ALPHA-2-GLYCOPROTEIN;

ACUTE HEMORRHAGIC PANCREATITIS; ACUTE LUNG INJURY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE PREDISPOSITION; EXPERIMENTAL RABBIT; HUMAN; IMMUNITY; INFLAMMATION; LUNG INJURY; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; OBESITY; PANDEMIC; PNEUMONIA; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPONECTIN; CYTOKINES; EYE PROTEINS; GPI-LINKED PROTEINS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LECTINS; LUNG INJURY; MEMBRANE PROTEINS; NF-KAPPA B; OBESITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-1; SEMINAL PLASMA PROTEINS; SERPINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901752742     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/978463     Document Type: Review

References (165)

1. Shaw K. A., Caughey A. B., Edelman A. B., Obesity epidemic: how to make a difference in a busy OB/GYN practice. Obstetrical & Gynecological Survey 2012 67 6 365 373 10.1097/OGX.0b013e318259ee6a
2. Flegal K. M., Carroll M. D., Ogden C. L., Curtin L. R., Prevalence and trends in obesity among US adults, 1999-2008. Journal of the American Medical Association 2010 303 3 235 241 2-s2.0-74549140993 10.1001/jama.2009.2014
3. Gong M. N., Bajwa E. K., Thompson B. T., Christiani D. C., Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 2010 65 1 44 50 2-s2.0-73449111601 10.1136/thx.2009.117572
4. Lederer D. J., Kawut S. M., Wickersham N., Winterbottom C., Bhorade S., Palmer S. M., Lee J., Diamond J. M., Wille K. M., Weinacker A., Lama V. N., Crespo M., Orens J. B., Sonett J. R., Arcasoy S. M., Ware L. B., Christie J. D., Obesity and primary graft dysfunction after lung transplantation: the lung transplant outcomes group obesity study. American Journal of Respiratory and Critical Care Medicine 2011 184 9 1055 1061 2-s2.0-81055155530 10.1164/rccm.201104-0728OC
5. Gajic O., Dabbagh O., Park P. K., Adesanya A., Chang S. Y., Hou P., Anderson H. III, Hoth J. J., Mikkelsen M. E., Gentile N. T., Gong M. N., Talmor D., Bajwa E., Watkins T. R., Festic E., Yilmaz M., Iscimen R., Kaufman D. A., Esper A. M., Sadikot R., Douglas I., Sevransky J., Malinchoc M., Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. American Journal of Respiratory and Critical Care Medicine 2011 183 4 462 470 2-s2.0-78650060535 10.1164/rccm.201004-0549OC
6. Mancuso P., Obesity and lung inflammation. Journal of Applied Physiology 2010 108 3 722 728 2-s2.0-77949716009 10.1152/japplphysiol.00781.2009
7. Hack C. E., Aarden L. A., Thijs L. G., Role of cytokines in sepsis. Advances in Immunology 1997 66 101 195 2-s2.0-0030963768 (Pubitemid 27430942)
8. Thijs L. G., Hack C. E., Time course of cytokine levels in sepsis. Intensive Care Medicine 1995 21 supplement 2 S258 S263 2-s2.0-0000912790 10.1007/BF01740764
9. Bhatia M., Moochhala S., Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Journal of Pathology 2004 202 2 145 156 2-s2.0-1142299409 10.1002/path.1491 (Pubitemid 38208651)
10. Rubenfeld G. D., Caldwell E., Peabody E., Weaver J., Martin D. P., Neff M., Stern E. J., Hudson L. D., Incidence and outcomes of acute lung injury. New England Journal of Medicine 2005 353 16 1685 1693 2-s2.0-26844552488 10.1056/NEJMoa050333 (Pubitemid 41464707)
11. Reiss L. K., Uhlig U., Uhlig S., Models and mechanisms of acute lung injury caused by direct insults. European Journal of Cell Biology 2012 91 6-7 590 601 2-s2.0-84860255381 10.1016/j.ejcb.2011.11.004
12. Simpson S. Q., Casey L. C., Role of tumor necrosis factor in sepsis and acute lung injury. Critical Care Clinics 1989 5 1 27 47 2-s2.0-0024579679 (Pubitemid 19026072)
13. Klein C. L., Hoke T. S., Fang W., Altmann C. J., Douglas I. S., Faubel S., Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney International 2008 74 7 901 909 2-s2.0-51849138935 10.1038/ki.2008.314
14. Leal V. D. O., Mafra D., Adipokines in obesity. Clinica Chimica Acta 2013 419 87 94 10.1016/j.cca.2013.02.003
15. Olefsky J. M., Glass C. K., Macrophages, inflammation, and insulin resistance. Annual Review of Physiology 2009 72 219 246 2-s2.0-77951918926 10.1146/annurev-physiol-021909-135846
16. Strieter R. M., Belperio J. A., Keane M. P., Host innate defenses in the lung: the role of cytokines. Current Opinion in Infectious Diseases 2003 16 3 193 198 2-s2.0-0038282500 (Pubitemid 36677311)
17. Herder C., Carstensen M., Ouwens D. M., Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes, Obesity and Metabolism 2013 15 supplement 3 39 50
18. Tan B. K., Adya R., Randeva H. S., Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends in Cardiovascular Medicine 2010 20 5 143 148 2-s2.0-79960078829 10.1016/j.tcm.2010.12.002
19. Kralisch S., Klein J., Bluher M., Paschke R., Stumvoll M., Fasshauer M., Therapeutic perspectives of adipocytokines. Expert Opinion on Pharmacotherapy 2005 6 6 863 872 2-s2.0-21744460998 10.1517/14656566.6.6.863 (Pubitemid 40946152)
20. Calder P. C., Ahluwalia N., Brouns F., Buetler T., Clement K., Cunningham K., Esposito K., Jönsson L. S., Kolb H., Lansink M., Marcos A., Margioris A., Matusheski N., Nordmann H., O'Brien J., Pugliese G., Rizkalla S., Schalkwijk C., Tuomilehto J., Wärnberg J., Watzl B., Winklhofer-Roob B. M., Dietary factors and low-grade inflammation in relation to overweight and obesity. British Journal of Nutrition 2011 106 supplement 3 S5 S78 2-s2.0-82955170624
21. Berg A. H., Combs T. P., Scherer P. E., ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 2002 13 2 84 89 2-s2.0-0036511213 10.1016/S1043-2760(01)00524-0 (Pubitemid 36740452)
22. Scherer P. E., Williams S., Fogliano M., Baldini G., Lodish H. F., A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 1995 270 45 26746 26749 2-s2.0-0028787490 10.1074/jbc.270.45.26746
23. Shapiro L., Scherer P. E., The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Current Biology 1998 8 6 335 338 2-s2.0-0032510463 (Pubitemid 28159119)
24. Piñeiro R., Iglesias M. J., Gallego R., Raghay K., Eiras S., Rubio J., Diéguez C., Gualillo O., González-Juanatey J. R., Lago F., Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Letters 2005 579 23 5163 5169 2-s2.0-24944532986 10.1016/j.febslet.2005.07.098 (Pubitemid 41318086)
25. Wang Y., Lau W. B., Gao E., Tao L., Yuan Y., Li R., Wang X., Koch W. J., Ma X., Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. American Journal of Physiology-Endocrinology and Metabolism 2010 298 3 E663 E670 2-s2.0-77349124428 10.1152/ajpendo.00663.2009
26. Delaigle A. M., Senou M., Guiot Y., Many M.-C., Brichard S. M., Induction of adiponectin in skeletal muscle of type 2 diabetic mice: in vivo and in vitro studies. Diabetologia 2006 49 6 1311 1323 2-s2.0-33646496789 10.1007/s00125-006-0210-y
27. Van Berendoncks A. M., Garnier A., Beckers P., Hoymans V. Y., Possemiers N., Fortin D., Martinet W., Van Hoof V., Vrints C. J., Ventura-Clapier R., Conraads V. M., Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circulation: Heart Failure 2010 3 2 185 194 2-s2.0-77951891596 10.1161/CIRCHEARTFAILURE.109.885525
28. Turer A. T., Scherer P. E., Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012 55 9 2319 2326 10.1007/s00125-012-2598- x
29. Tilg H., Moschen A. R., Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clinical Science 2008 114 3-4 275 288 2-s2.0-38949106690 10.1042/CS20070196 (Pubitemid 351294003)
30. Turer A. T., Khera A., Ayers C. R., Turer C. B., Grundy S. M., Vega G. L., Scherer P. E., Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011 54 10 2515 2524 2-s2.0-80054094657 10.1007/s00125-011-2252-z
31. Kizer J. R., A tangled threesome: adiponectin, insulin sensitivity, and adiposity: can mendelian randomization sort out causality? Diabetes 2013 62 4 1007 1009 10.2337/db12-1673
32. Hoffstedt J., Arvidsson E., Sjölin E., Wåhlén K., Arner P., Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2004 89 3 1391 1396 2-s2.0-1642299047 10.1210/jc.2003-031458 (Pubitemid 38368442)
33. Schulze M. B., Shai I., Rimm E. B., Li T., Rifai N., Hu F. B., Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005 54 2 534 539 2-s2.0-12744269196 10.2337/diabetes.54.2. 534
34. Padmalayam I., Suto M., Role of adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy. Current Pharmaceutical Design 2013 19 32 5755 5763 10.2174/13816128113199990360
35. Maahs D. M., Ogden L. G., Snell-Bergeon J. K., Kinney G. L., Wadwa R. P., Hokanson J. E., Dabelea D., Kretowski A., Eckel R. H., Rewers M., Determinants of serum adiponectin in persons with and without type 1 diabetes. American Journal of Epidemiology 2007 166 6 731 740 2-s2.0-34548303757 10.1093/aje/kwm125 (Pubitemid 47347894)
36. Leth H., Andersen K. K., Frystyk J., Tarnow L., Rossing P., Parving H., Flyvbjerg A., Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 2008 93 8 3186 3191 2-s2.0-49249105845 10.1210/jc.2008-0360
37. Semple R. K., Halberg N. H., Burling K., Soos M. A., Schraw T., Luan J., Cochran E. K., Dunger D. B., Wareham N. J., Scherer P. E., Gorden P., O'Rahilly S., Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007 56 6 1712 1717 2-s2.0-34249693131 10.2337/db06-1665 (Pubitemid 46842611)
38. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A. M., Danesh J., Whincup P. H., Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006 114 7 623 629 2-s2.0-33746745255 10.1161/CIRCULATIONAHA.106.618918 (Pubitemid 44252303)
39. Landskroner-Eiger S., Qian B., Muise E. S., Nawrocki A. R., Berger J. P., Fine E. J., Koba W., Deng Y., Pollard J. W., Scherer P. E., Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clinical Cancer Research 2009 15 10 3265 3276 2-s2.0-66149164443 10.1158/1078-0432.CCR-08-2649
40. Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M., Yamaguchi M., Namiki S., Nakayama R., Tabata M., Ogata H., Kubota N., Takamoto I., Hayashi Y. K., Yamauchi N., Waki H., Fukayama M., Nishino I., Tokuyama K., Ueki K., Oike Y., Ishii S., Hirose K., Shimizu T., Touhara K., Kadowaki T., Adiponectin and AdipoR1 regulate PGC-1 α and mitochondria by Ca 2+ and AMPK/SIRT1. Nature 2010 464 7293 1313 1319 2-s2.0-77951872309 10.1038/nature08991
41. Klöting N., Fasshauer M., Dietrich A., Kovacs P., Schön M. R., Kern M., Stumvoll M., Blüher M., Insulin-sensitive obesity. American Journal of Physiology-Endocrinology and Metabolism 2010 299 3 E506 E515 2-s2.0-77956696547 10.1152/ajpendo.00586.2009
42. Sun K., Kusminski C. M., Scherer P. E., Adipose tissue remodeling and obesity. Journal of Clinical Investigation 2011 121 6 2094 2101 2-s2.0-79957916782 10.1172/JCI45887
43. Wang S., Sparks L. M., Xie H., Greenway F. L., De Jonge L., Smith S. R., Subtyping obesity with microarrays: implications for the diagnosis and treatment of obesity. International Journal of Obesity 2009 33 4 481 489 2-s2.0-64849088864 10.1038/ijo.2008.277
44. Dietze-Schroeder D., Sell H., Uhlig M., Koenen M., Eckel J., Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005 54 7 2003 2011 2-s2.0-21344449294 10.2337/diabetes.54.7.2003 (Pubitemid 40911262)
45. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kubota N., Kaneko K., Kobayashi M., Iwane A., Sasako T., Okazaki Y., Ohsugi M., Takamoto I., Yamashita S., Asahara H., Akira S., Kasuga M., Kadowaki T., Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metabolism 2011 13 4 401 412 2-s2.0-79953765855 10.1016/j.cmet.2011.02.010
46. Holland W. L., Miller R. A., Wang Z. V., Sun K., Barth B. M., Bui H. H., Davis K. E., Bikman B. T., Halberg N., Rutkowski J. M., Wade M. R., Tenorio V. M., Kuo M., Brozinick J. T., Zhang B. B., Birnbaum M. J., Summers S. A., Scherer P. E., Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature Medicine 2011 17 1 55 63 2-s2.0-78651260799 10.1038/nm.2277
47. Asterholm I. W., Scherer P. E., Enhanced metabolic flexibility associated with elevated adiponectin levels. American Journal of Pathology 2010 176 3 1364 1376 2-s2.0-77749242629 10.2353/ajpath.2010.090647
48. Xin X., Zhou L., Reyes C. M., Liu F., Dong L. Q., APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway. American Journal of Physiology-Endocrinology and Metabolism 2011 300 1 E103 E110 2-s2.0-78650795768 10.1152/ajpendo.00427.2010
49. Hug C., Wang J., Ahmad N. S., Bogan J. S., Tsao T., Lodish H. F., T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proceedings of the National Academy of Sciences of the United States of America 2004 101 28 10308 10313 2-s2.0-3142761477 10.1073/pnas.0403382101 (Pubitemid 38924921)
50. Rao J. R., Keating D. J., Chen C., Parkington H. C., Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPAR γ -dependent and PPAR γ -independent mechanisms. Diabetes, Obesity and Metabolism 2012 14 11 983 989 10.1111/j.1463-1326.2012.01626.x
51. Wijesekara N., Krishnamurthy M., Bhattacharjee A., Suhail A., Sweeney G., Wheeler M. B., Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. Journal of Biological Chemistry 2010 285 44 33623 33631 2-s2.0-77958568034 10.1074/jbc.M109.085084
52. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kaneko K., Okazaki Y., Bardeesy N., Ohnishi S., Nagai R., Kadowaki T., Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochemical and Biophysical Research Communications 2009 382 1 51 56 2-s2.0-63149189738 10.1016/j.bbrc.2009.02.131
53. Ohashi K., Parker J. L., Ouchi N., Higuchi A., Vita J. A., Gokce N., Pedersen A. A., Kalthoff C., Tullin S., Sams A., Summer R., Walsh K., Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. Journal of Biological Chemistry 2010 285 9 6153 6160 2-s2.0-77949881805 10.1074/jbc.M109.088708
54. Luo N., Wang X., Chung B. H., Lee M., Klein R. L., Garvey W. T., Fu Y., Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo. American Journal of Physiology-Endocrinology and Metabolism 2011 301 1 E180 E186 2-s2.0-79959603581 10.1152/ajpendo.00614.2010
55. Engeli S., Feldpausch M., Gorzelniak K., Hartwig F., Heintze U., Janke J., Möhlig M., Pfeiffer A. F. H., Luft F. C., Sharma A. M., Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003 52 4 942 947 2-s2.0-0037380664 10.2337/diabetes.52.4.942 (Pubitemid 36384264)
56. Krakoff J., Funahashi T., Stehouwer C. D. A., Schalkwijk C. G., Tanaka S., Matsuzawa Y., Kobes S., Tataranni P. A., Hanson R. L., Knowler W. C., Lindsay R. S., Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003 26 6 1745 1751 2-s2.0-10744231067 10.2337/diacare.26.6.1745 (Pubitemid 36929114)
57. Ouchi N., Kihara S., Funahashi T., Nakamura T., Nishida M., Kumada M., Okamoto Y., Ohashi K., Nagaretani H., Kishida K., Nishizawa H., Maeda N., Kobayashi H., Hiraoka H., Matsuzawa Y., Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003 107 5 671 674 2-s2.0-0037432152 10.1161/01.CIR.0000055188.83694.B3 (Pubitemid 36222590)
58. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
59. Mancuso P., Obesity and lung inflammation. Journal of Applied Physiology 2010 108 3 722 728 2-s2.0-77949716009 10.1152/japplphysiol.00781.2009
60. Nakatsuji H., Kobayashi H., Kishida K., Nakagawa T., Takahashi S., Tanaka H., Akamatsu S., Funahashi T., Shimomura I., Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio. Metabolism 2013 62 1 109 120 10.1016/j.metabol.2012.06. 006
61. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Kara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N. H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T., Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2004 423 762 769 2-s2.0-19644401011 10.1038/nature03091 (Pubitemid 39472238)
62. Sliman S. M., Patel R. B., Cruff J. P., Kotha S. R., Newland C. A., Schrader C. A., Sherwani S. I., Gurney T. O., Magalang U. J., Parinandi N. L., Adiponectin protects against hyperoxic lung injury and vascular leak. Cell Biochemistry and Biophysics 2013 67 2 399 414 2-s2.0-83455250386 10.1007/s12013-011-9330-1
63. Konter J. M., Parker J. L., Baez E., Li S. Z., Ranscht B., Denzel M., Little F. F., Nakamura K., Ouchi N., Fine A., Walsh K., Summer R. S., Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. Journal of Immunology 2012 188 2 854 863 2-s2.0-84855991252 10.4049/jimmunol.1100426
64. Orfanos S. E., Mavrommati I., Korovesi I., Roussos C., Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Medicine 2004 30 9 1702 1714 2-s2.0-4644293107 10.1007/s00134-004-2370-x (Pubitemid 39297172)
65. Tsushima K., King L. S., Aggarwal N. R., De Gorordo A., D'Alessio F. R., Kubo K., Acute lung injury review. Internal Medicine 2009 48 9 621 630 2-s2.0-67650092690 10.2169/internalmedicine.48.1741
66. Stapleton R. D., Dixon A. E., Parsons P. E., Ware L. B., Suratt B. T., The association between BMI and plasma cytokine levels in patients with acute lung injury. Chest 2010 138 3 568 577 2-s2.0-77956807510 10.1378/chest.10-0014
67. Gong M. N., Bajwa E. K., Thompson B. T., Christiani D. C., Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 2010 65 1 44 50 2-s2.0-73449111601 10.1136/thx.2009.117572
68. Towfigh S., Peralta M. V., Martin M. J., Salim A., Kelso R., Sohn H., Berne T. V., Mason R. J., Acute respiratory distress syndrome in nontrauma surgical patients: a 6-year study. Journal of Trauma-Injury, Infection and Critical Care 2009 67 6 1239 1243 2-s2.0-73949146140 10.1097/TA.0b013e31818b1733
69. Anzueto A., Frutos-Vivar F., Esteban A., Bensalami N., Marks D., Raymondos K., Apezteguía C., Arabi Y., Hurtado J., González M., Tomicic V., Abroug F., Elizalde J., Cakar N., Pelosi P., Ferguson N. D., Influence of body mass index on outcome of the mechanically ventilated patients. Thorax 2011 66 1 66 73 2-s2.0-78650189476 10.1136/thx.2010.145086
70. Gajic O., Dabbagh O., Park P. K., Adesanya A., Chang S. Y., Hou P., Anderson H. III, Hoth J. J., Mikkelsen M. E., Gentile N. T., Gong M. N., Talmor D., Bajwa E., Watkins T. R., Festic E., Yilmaz M., Iscimen R., Kaufman D. A., Esper A. M., Sadikot R., Douglas I., Sevransky J., Malinchoc M., Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. American Journal of Respiratory and Critical Care Medicine 2011 183 4 462 470 2-s2.0-78650060535 10.1164/rccm.201004-0549OC
71. Shibata R., Sato K., Pimentel D. R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K., Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nature Medicine 2005 11 10 1096 1103 2-s2.0-27144457438 10.1038/nm1295 (Pubitemid 41486832)
72. Summer R., Little F. F., Ouchi N., Takemura Y., Aprahamian T., Dwyer D., Fitzsimmons K., Suki B., Parameswaran H., Fine A., Walsh K., Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. American Journal of Physiology-Lung Cellular and Molecular Physiology 2008 294 6 L1035 L1042 2-s2.0-48949119345 10.1152/ajplung.00397.2007
73. Rokni Yazdi H., Lari S., Attaran D., Ayatollahi H., Mohsenizadeh A., The serum levels of adiponectin and leptin in mustard lung patients. Human & Experimental Toxicology 2013
74. Walkey A. J., Rice T. W., Konter J., Ouchi N., Shibata R., Walsh K., Deboisblanc B. P., Summer R., Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Critical Care Medicine 2010 38 12 2329 2334 2-s2.0-78650307893 10.1097/CCM.0b013e3181fa0561
75. Walkey A. J., Rice T. W., Konter J., Ouchi N., Shibata R., Walsh K., Deboisblanc B. P., Summer R., Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Critical Care Medicine 2010 38 12 2329 2334 2-s2.0-78650307893 10.1097/CCM.0b013e3181fa0561
76. Garcia P., Sood A., Adiponectin in pulmonary disease and critically ill patients. Current Medicinal Chemistry 2012 19 32 5493 5500 10.2174/ 092986712803833263
77. Leivo-Korpela S., Lehtimäki L., Vuolteenaho K., Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD. Respiratory Medicine 2014 108 1 122 128
78. Ohashi K., Parker J. L., Ouchi N., Higuchi A., Vita J. A., Gokce N., Pedersen A. A., Kalthoff C., Tullin S., Sams A., Summer R., Walsh K., Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. Journal of Biological Chemistry 2010 285 9 6153 6160 2-s2.0-77949881805 10.1074/jbc.M109.088708
79. Summer R., Little F. F., Ouchi N., Takemura Y., Aprahamian T., Dwyer D., Fitzsimmons K., Suki B., Parameswaran H., Fine A., Walsh K., Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. American Journal of Physiology-Lung Cellular and Molecular Physiology 2008 294 6 L1035 L1042 2-s2.0-48949119345 10.1152/ajplung.00397.2007
80. Shore S. A., Terry R. D., Flynt L., Xu A., Hug C., Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. Journal of Allergy and Clinical Immunology 2006 118 2 389 395 2-s2.0-33746516349 10.1016/j.jaci.2006.04.021 (Pubitemid 44142709)
81. Aprahamian T., Bonegio R. G., Richez C., Yasuda K., Chiang L., Sato K., Walsh K., Rifkin I. R., The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. Journal of Immunology 2009 182 1 340 346 2-s2.0-59849087383
82. Nishizawa H., Shimomura L., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y., Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002 51 9 2734 2741 2-s2.0-0036724336 (Pubitemid 34970926)
83. Yang R. Z., Lee M., Hu H., Pray J., Wu H., Hansen B. C., Shuldiner A. R., Fried S. K., McLenithan J. C., Gong D., Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of Physiology-Endocrinology and Metabolism 2006 290 6 E1253 E1261 2-s2.0-33744932403 10.1152/ajpendo.00572.2004 (Pubitemid 43847911)
84. Catli G., Anik A., Abaci A., Kume T., Bober E., Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Experimental and Clinical Endocrinology & Diabetes 2013 121 10 595 600 10.1055/s-0033-1355338
85. De Souza Batista C. M., Yang R., Lee M., Glynn N. M., Yu D., Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried S. K., Gong D., Shuldiner A. R., Pollin T. I., McLenithan J. C., Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007 56 6 1655 1661 2-s2.0-34249674520 10.2337/db06-1506 (Pubitemid 46842600)
86. Yan P., Liu D., Long M., Ren Y., Pang J., Li R., Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2011 119 4 257 263 2-s2.0-79953816011 10.1055/s-0030-1269912
87. Saremi A., Asghari M., Ghorbani A., Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. Journal of Sports Sciences 2010 28 9 993 998 2-s2.0-77954233083 10.1080/02640414.2010. 484070
88. Pan H. Y., Guo L., Li Q., Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Research and Clinical Practice 2010 88 1 29 33 2-s2.0-77649232845 10.1016/j.diabres.2010.01.013
89. Moreno-Navarrete J. M., Cataln V., Ortega F., Gámez-Ambrosi J., Ricart W., Frühbeck G., Fernndez-Real J. M., Circulating omentin concentration increases after weight loss. Nutrition and Metabolism 2010 7 27 2-s2.0-77950663316 10.1186/1743-7075-7-27
90. Tan B. K., Adya R., Farhatullah S., Chen J., Lehnert H., Randeva H. S., Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010 59 12 3023 3031 10.2337/db10-0124
91. Esteghamati A., Noshad S., Rabizadeh S., Ghavami M., Zandieh A., Nakhjavani M., Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regulatory Peptides 2013 182 1 6 10.1016/j.regpep.2012.12.005
92. Siejkaa A., Jankiewicz-Wikaa J., Kolomeckib K., Cywinskic J., Piestrzeniewiczd K., Swietoslawskie J., Stepienf H., Komorowskia J., Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine 2013 64 2 490 493
93. Schäffler A., Neumeier M., Herfarth H., Fürst A., Schölmerich J., Büchler C., Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta-Gene Structure and Expression 2005 1732 1-3 96 102 2-s2.0-33144479356 10.1016/j.bbaexp.2005.11.005 (Pubitemid 43267310)
94. Šenolt L., Polanská M., Filková M., Cerezo L. A., Pavelka K., Gay S., Haluzík M., Vencovský J., Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 7 1410 1411 2-s2.0-77954972021 10.1136/ard.2009.119735
95. de Souza Batista C. M., Yang R., Lee M., Glynn N. M., Yu D., Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried S. K., Gong D., Shuldiner A. R., Pollin T. I., McLenithan J. C., Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007 56 6 1655 1661 2-s2.0-34249674520 10.2337/db06-1506 (Pubitemid 46842600)
96. Yamawaki H., Kuramoto J., Kameshima S., Usui T., Okada M., Hara Y., Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and Biophysical Research Communications 2011 408 2 339 343 2-s2.0-79955662090 10.1016/j.bbrc.2011.04.039
97. Kazama K., Usui T., Okada M., Hara Y., Yamawaki H., Omentin plays an anti-inflammatory role through inhibition of TNF- α -induced superoxide production in vascular smooth muscle cells. European Journal of Pharmacology 2012 686 1-3 116 123 10.1016/j.ejphar.2012.04.033
98. Zhong X., Li X., Liu F., Tan H., Shang D., Omentin inhibits TNF- α -induced expression of adhesion molecules in endothelial cells via ERK/NF- B pathway. Biochemical and Biophysical Research Communications 2012 425 2 401 406 10.1016/j.bbrc.2012.07.110
99. Kazama K., Usui T., Okada M., Hara Y., Yamawaki H., Omentin plays an anti-inflammatory role through inhibition of TNF- α -induced superoxide production in vascular smooth muscle cells. European Journal of Pharmacology 2012 686 1-3 116 123 10.1016/j.ejphar.2012.04.033
100. Yamawaki H., Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biological and Pharmaceutical Bulletin 2011 34 3 307 310 2-s2.0-79952333682 10.1248/bpb.34.307
101. Zirlik S., Hildner K., Targosz A., Neurath M. F., Fuchs F. S., Brzozowski T., Konturek P. C., Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? Journal of Physiology and Pharmacology 2013 64 3 353 360
102. Wang Q., Feng X., Zhou C., Li P., Kang J., Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Annals of Clinical Biochemistry 2013 50 part 3 230 235
103. Kurt O. K., Tosun M., Alcelik A., Yilmaz B., Talay F., Serum omentin levels in patients with obstructive sleep apnea. Sleep Breath 2013
104. Ouchi N., Higuchi A., Ohashi K., Oshima Y., Gokce N., Shibata R., Akasaki Y., Shimono A., Walsh K., Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010 329 5990 454 457 2-s2.0-77954844177 10.1126/science.1188280
105. Schulte D. M., Müller N., Neumann K., Oberhäuser F., Faust M., Güdelhöfer H., Brandt B., Krone W., Laudes M., Pro-inflammatory wnt5a and anti-inflammatory sfrp5 are differentially regulated by nutritional factors in obese human subjects. PLoS ONE 2012 7 2 2-s2.0-84857545934 10.1371/journal.pone.0032437 e32437
106. Ehrlund A., Mejhert N., Lorente-Cebrián S., Aström G., Dahlman I., Laurencikiene J., Rydén M., Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. Journal of Clinical Endocrinology & Metabolism 2013 98 3 E503 E508 10.1210/jc.2012-3416
107. Mori H., Prestwich T. C., Reid M. A., Longo K. A., Gerin I., Cawthorn W. P., Susulic V. S., Krishnan V., Greenfield A., Macdougald O. A., Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. Journal of Clinical Investigation 2012 122 7 2405 2416
108. Xavier C. P., Melikova M., Chuman Y., Uren A., Baljinnyam B., Rubin J. S., Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/ β -catenin signaling. Cellular Signalling 2014 26 1 94 101 10.1016/j.cellsig.2013.09.016
109. Zhu J., Wang Y., Duan J., Bai H., Wang Z., Wei L., Zhao J., Zhuo M., Wang S., Yang L., An T., Wu M., Wang J., DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research 2012 31 80 10.1186/1756-9966-31-80
110. Castro M., Grau L., Puerta P., Gimenez L., Venditti J., Quadrelli S., Sánchez-Carbayo M., Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. Journal of Translational Medicine 2010 8 86 2-s2.0-77957896015 10.1186/1479-5876-8-86
111. Lee A. Y., He B., You L., Dadfarmay S., Xu Z., Mazieres J., Mikami I., McCormick F., Jablons D. M., Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004 23 39 6672 6676 2-s2.0-4444343396 10.1038/sj.onc.1207881 (Pubitemid 39265531)
112. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., Hashimoto I., Okada T., Yasuhara A., Nakatsuka A., Shikata K., Hourai S., Futami J., Watanabe E., Matsuki Y., Hiramatsu R., Akagi S., Makino H., Kanwar Y. S., Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America 2005 102 30 10610 10615 2-s2.0-23044473651 10.1073/pnas.0504703102 (Pubitemid 41061602)
113. Klöting N., Kovacs P., Kern M., Heiker J. T., Fasshauer M., Schön M. R., Stumvoll M., Beck-Sickinger A. G., Blüher M., Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 2011 54 7 1819 1823 2-s2.0-79959740793 10.1007/s00125-011-2137-1
114. Youn B. S., Klöting N., Kratzsch J., Lee N., Park J. W., Song E., Ruschke K., Oberbach A., Fasshauer M., Stumvoll M., Blüher M., Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008 57 2 372 377 2-s2.0-40749155505 10.2337/db07-1045
115. Schultz S., Beck-Sickinger A. G., Chemerin and vaspin: possible targets to treat obesity? ChemMedChem 2013 8 4 549 559 10.1002/cmdc.201200448
116. Handisurya A., Riedl M., Vila G., Maier C., Clodi M., Prikoszovich T., Ludvik B., Prager G., Luger A., Kautzky-Willer A., Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obesity Surgery 2010 20 2 198 203 2-s2.0-77949273953 10.1007/s11695-009-9882-y
117. Sell H., Divoux A., Poitou C., Basdevant A., Bouillot J., Bedossa P., Tordjman J., Eckel J., Clément K., Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 2010 95 6 2892 2896 2-s2.0-77954471976 10.1210/jc.2009-2374
118. Tan B. K., Heutling D., Chen J., Farhatullah S., Adya R., Keay S. D., Kennedy C. R., Lehnert H., Randeva H. S., Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008 57 6 1501 1507 2-s2.0-48249120025 10.2337/db08-0127
119. Morisaki T., Takeshima F., Fukuda H., Matsushima K., Akazawa Y., Yamaguchi N., Ohnita K., Isomoto H., Takeshita H., Sawai T., Fujita F., Nakao K., High serum vaspin concentrations in patients with ulcerative colitis. Digestive Diseases and Sciences 2013 59 2 315 521 10.1007/s10620-013-2905-5
120. Kim J. M., Kim T. N., Won J. C., Association between serum vaspin level and metabolic syndrome in healthy korean subjects. Metabolic Syndrome and Related Disorders 2013 11 6 385 391 10.1089/met.2013.0054
121. Li H., Peng W., Zhuang J., Lu Y., Jian W., Wei Y., Li W., Xu Y., Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF- B signaling pathways. Atherosclerosis 2013 228 1 61 68 10.1016/j.atherosclerosis.2013.02.013
122. Zahradka P., Inhibition of NADPH oxidase by vaspin may prevent progression of atherosclerosis. Acta Physiologica 2013 209 3 195 198
123. Cho J. K., Han T., Kang H. S., Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. European Journal of Applied Physiology 2010 108 2 347 353 2-s2.0-76449112359 10.1007/s00421-009-1238-8
124. Bing C., Bao Y., Jenkins J., Sanders P., Manieri M., Cinti S., Tisdale M. J., Trayhurn P., Zinc- α 2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proceedings of the National Academy of Sciences of the United States of America 2004 101 8 2500 2505 2-s2.0-1442330395 10.1073/pnas.0308647100 (Pubitemid 38269340)
125. Russell S. T., Tisdale M. J., Studies on the anti-obesity activity of zinc- α 2-glycoprotein in the rat. International Journal of Obesity 2011 35 5 658 665 2-s2.0-79955843362 10.1038/ijo.2010.193
126. Russell S. T., Tisdale M. J., Role of β -adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc- α 2-glycoprotien (ZAG). Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 2012 1821 4 590 599 2-s2.0-84857662172 10.1016/j.bbalip.2011.12.003
127. Bing C., Lipid mobilization in cachexia: mechanisms and mediators. Current Opinion in Supportive and Palliative Care 2011 5 4 356 360 2-s2.0-84856920747 10.1097/SPC.0b013e32834bde0e
128. Bing C., Mracek T., Gao D., Trayhurn P., Zinc- α 2-glycoprotein: an adipokine modulator of body fat mass. International Journal of Obesity 2010 34 11 1559 1565 2-s2.0-78349308886 10.1038/ijo.2010.105
129. Russell S. T., Tisdale M. J., Studies on the antiobesity effect of zinc- α 2-glycoprotein in the ob/ob mouse. International Journal of Obesity 2011 35 3 345 354 2-s2.0-79952696498 10.1038/ijo.2010.150
130. Selva D. M., Lecube A., Hernández C., Baena J. A., Fort J. M., Simó R., Lower zinc- α 2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. Journal of Clinical Endocrinology and Metabolism 2009 94 11 4499 4507 2-s2.0-70449091943 10.1210/jc.2009-0758
131. Yang M., Liu R., Li S., Luo Y., Zhang Y., Zhang L., Liu D., Wang Y., Xiong Z., Boden G., Chen S., Li L., Yang G., Zinc- α 2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 2013 36 5 1074 1082 10.2337/dc12-0940
132. Yeung D. C., Lam K. S., Wang Y., Tso A. W., Xu A., Serum zinc- α 2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. Journal of Clinical Endocrinology and Metabolism 2009 94 7 2531 2536 2-s2.0-67650224490 10.1210/jc.2009-0058
133. Pelletier C. C., Koppe L., Croze M. L., Kalbacher E., Vella R. E., Guebre-Egziabher F., Géloën A., Badet L., Fouque D., Soulage C. O., White adipose tissue overproduces the lipid-mobilizing factor zinc α 2-glycoprotein in chronic kidney disease. Kidney International 2013 83 5 878 886 10.1038/ki.2013.9
134. Gao D., Trayhurn P., Bing C., Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Molecular and Cellular Endocrinology 2010 325 1-2 135 142 2-s2.0-77954382777 10.1016/j.mce.2010.05.020
135. Leal V. O., Lobo J. C., Stockler-Pinto M. B., Farage N. E., Abdalla D. S. P., Leite M. Jr., Mafra D., Is zinc- α 2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clinica Chimica Acta 2012 413 5-6 616 619 2-s2.0-84856224604 10.1016/j.cca.2011.12.002
136. Mracek T., Ding Q., Tzanavari T., Kos K., Pinkney J., Wilding J., Trayhurn P., Bing C., The adipokine zinc- α 2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clinical Endocrinology 2010 72 3 334 341 2-s2.0-76649083327 10.1111/j.1365-2265.2009.03658.x
137. Ceperuelo-Mallafré V., Näf S., Escoté X., Caubet E., Gomez J. M., Miranda M., Chacon M. R., Gonzalez-Clemente J. M., Gallart L., Gutierrez C., Vendrell J., Circulating and adipose tissue gene expression of zinc- α 2- glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. Journal of Clinical Endocrinology and Metabolism 2009 94 12 5062 5069 2-s2.0-73249153045 10.1210/jc.2009-0764
138. Marrades M. P., Martínez J. A., Moreno-Aliaga M. J., ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. Journal of Physiology and Biochemistry 2008 64 1 61 66 2-s2.0-47349116896 (Pubitemid 351997494)
139. Hong E., Hwi J. K., Cho Y., Kim H., Ma Z., Yu T. Y., Friedline R. H., Kurt-Jones E., Finberg R., Fischer M. A., Granger E. L., Norbury C. C., Hauschka S. D., Philbrick W. M., Lee C., Elias J. A., Kim J. K., Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 2009 58 11 2525 2535 2-s2.0-70350561703 10.2337/db08-1261
140. van Exel E., Gussekloo J., de Craen A. J., Frölich M., Wiel A. B. D., Westendorp R. G. J., Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-plus study. Diabetes 2002 51 4 1088 1092 2-s2.0-0036224269 (Pubitemid 34438354)
141. Herder C., Carstensen M., Ouwens D. M., Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes, Obesity and Metabolism 2013 15 supplement 3 39 50
142. Banchereau J., Pascual V., O'Garra A., From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nature Immunology 2012 13 10 925 931 10.1038/ni.2406
143. Bustos M. L., Huleihela L., Meyer E. M., Donnenberg A. D., Donnenberg V. S., Sciurba J. D., Mroz L., McVerry B. J., Ellis B. M., Kaminski N., Rojas M., Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Translational Medicine 2013 2 11 884 895 10.5966/sctm.2013-0033
144. Itano H., Zhang W., Ritter J. H., McCarthy T. J., Mohanakumar T., Patterson G. A., Adenovirus-mediated gene transfer of human interleukin 10 ameliorates reperfusion injury of rat lung isografts. Journal of Thoracic and Cardiovascular Surgery 2000 120 5 947 956 2-s2.0-0033746304
145. Standiford T. J., Strieter R. M., Lukacs N. W., Kunkel S. L., Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. Journal of Immunology 1995 155 4 2222 2229 2-s2.0-0029164732
146. Grool T. A., van Dullemen H., Meenan J., Koster F., Ten Kate F. J. W., Lebeaut A., Tytgat G. N. J., Van Deventer S. J. H., Anti-inflammatory effect of interleukin-10 in rabbit immune complexinduced colitis. Scandinavian Journal of Gastroenterology 1998 33 7 754 758 2-s2.0-0031821859 10.1080/00365529850171710 (Pubitemid 28358061)
147. Kurte M., López M., Aguirre A., Escobar A., Aguillón J. C., Charo J., Larsen C. G., Kiessling R., Salazar-Onfray F., A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. Journal of Immunology 2004 173 3 1731 1737 2-s2.0-3242799553 (Pubitemid 38971604)
148. López M. N., Pesce B., Kurte M., Pérez C., Segal G., Roa J., Aguillón J. C., Mendoza-Naranjo A., Gesser B., Larsen C., Villablanca A., Choudhury A., Kiessling R., Salazar-Onfray F., A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF- β + tolerogenic dendritic cells. Immunobiology 2011 216 10 1117 1126 2-s2.0-80052097089 10.1016/j.imbio.2011.04.006
149. Osman M. O., Jacobsen N. O., Kristensen J. U., Deleuran B., Gesser B., Larsen C. G., Jensen S. L., It 9302, a synthetic interleukin-10 agonist diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery 1998 124 3 584 592 2-s2.0-0031668057 10.1016/S0039-6060(98)70106-0 (Pubitemid 28413357)
150. Osman M. O., Gesser B., Mortensen J. T., Matsushima K., Jensen S. L., Larsen C. G., Profiles of pro-inflammatory cytokines in the serum of rabbits after experimentally induced acute pancreatitis. Cytokine 2002 17 1 53 59 2-s2.0-0036057031 10.1006/cyto.2001.0977
151. Carstensen M., Herder C., Kivimäki M., Jokela M., Roden M., Shipley M. J., Witte D. R., Brunner E. J., Tabák A. G., Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 2010 59 5 1222 1227 2-s2.0-77951831569 10.2337/db09-1199
152. Larsen C. M., Faulenbach M., Vaag A., Vølund A., Ehses J. A., Seifert B., Mandrup-Poulsen T., Donath M. Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine 2007 356 15 1517 1526 2-s2.0-34247170807 10.1056/NEJMoa065213 (Pubitemid 46588416)
153. van Asseldonk E. J. P., Stienstra R., Koenen T. B., Joosten L. A. B., Netea M. G., Tack C. J., Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2011 96 7 2119 2126 2-s2.0-79960086288 10.1210/jc.2010-2992
154. Aksentijevich I., Masters S. L., Ferguson P. J., Dancey P., Frenkel J., Van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E. W., Pham T., Booty M., Estes J. D., Sandler N. G., Plass N., Stone D. L., Turner M. L., Hill S., Butman J. A., Schneider R., Babyn P., El-Shanti H. I., Pope E., Barron K., Bing X., Laurence A., Lee C. R., Chapelle D., Clarke G. I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B. D., Gregersen P. K., Van Martin Hagen P., Hak A. E., Huizing M., Rahman P., Douek D. C., Remmers E. F., Kastner D. L., Goldbach-Mansky R., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. New England Journal of Medicine 2009 360 23 2426 2437 2-s2.0-66649121678 10.1056/NEJMoa0807865
155. Herold S., Tabar T., Janßen H., Hoegner K., Cabanski M., Lewe-Schlosser P., Albrecht J., Driever F., Vadasz I., Seeger W., Steinmueller M., Lohmeyer J., Exudate macrophages attenuate lung injury by the release of IL-1 receptor antagonist in gram-negative pneumonia. American Journal of Respiratory and Critical Care Medicine 2011 183 10 1380 1390 2-s2.0-79956200862 10.1164/rccm.201009-1431OC
156. Banchereau J., Pascual V., O'Garra A., From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nature Immunology 2012 13 10 925 931
157. Li M. O., Flavell R. A., Contextual regulation of inflammation: a duet by transforming growth factor- β and interleukin-10. Immunity 2008 28 4 468 476 2-s2.0-41549169557 10.1016/j.immuni.2008.03.003 (Pubitemid 351467045)
158. Zamani N., Brown C. W., Emerging roles for the transforming growth factor- β superfamily in regulating adiposity and energy expenditure. Endocrine Reviews 2011 32 3 387 403 2-s2.0-79958242398 10.1210/er.2010-0018
159. Kempf T., Guba-Quint A., Torgerson J., Magnone M. C., Haefliger C., Bobadilla M., Wollert K. C., Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. European Journal of Endocrinology 2012 167 5 671 678 10.1530/EJE-12-0466
160. Vila G., Riedl M., Anderwald C., Resl M., Handisurya A., Clodi M., Prager G., Ludvik B., Krebs M., Luger A., The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clinical Chemistry 2011 57 2 309 316 2-s2.0-79551498280 10.1373/clinchem.2010.153726
161. Macia L., Tsai V., Nguyen A. D., Johnen H., Kuffner T., Shi Y., Lin S., Herzog H., Brown D. A., Breit S. N., Sainsbury A., Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS ONE 2012 7 4 2-s2.0-84859733519 10.1371/journal.pone.0034868 e34868
162. Yanaba K., Asano Y., Tada Y., Sugaya M., Kadono T., Sato S., Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Modern Rheumatology 2012. 22(5): p. 668-675 22 5 668 675 2-s2.0-82655165820 10.1007/s10165-011-0568-7
163. Otvos L. Jr., Haspinger E., LaRussa F., Maspero F., Graziano P., Kovalszky I., Lovas S., Nama K., Hoffmann R., Knappe D., Cassone M., Wade J., Surmacz E., Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnology 2011 11 90 2-s2.0-80053478017 10.1186/1472-6750-11-90
164. Osman M. O., Jacobsen N. O., Kristensen J. U., Deleuran B., Gesser B., Larsen C. G., Jensen S. L., It 9302, a synthetic interleukin-10 agonist diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery 1998 124 3 584 592 2-s2.0-0031668057 10.1016/S0039-6060(98)70106-0 (Pubitemid 28413357)
165. López M. N., Pesce B., Kurte M., Pérez C., Segal G., Roa J., Aguillón J. C., Mendoza-Naranjo A., Gesser B., Larsen C., Villablanca A., Choudhury A., Kiessling R., Salazar-Onfray F., A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF- β + tolerogenic dendritic cells. Immunobiology 2011 216 10 1117 1126 2-s2.0-80052097089 10.1016/j.imbio.2011.04.006